Roger E. Turbin

About

Dr. Roger E. Turbin is a highly distinguished Professor of Ophthalmology at Rutgers New Jersey Medical School. He completed his undergraduate degree from Washington University in St. Louis, MO, where he also obtained his Doctor of Medicine in 1993. Dr. Turbin completed an internship at the University of Utah School of Medicine and his residency at NYU. He is a highly respected expert and leader in the field of neuro-ophthalmology as well as orbital and oculoplastic surgery. Dr. Turbin often serves as an attending on-call trauma surgeon for plastic and neuro-ophthalmology at University Hospital in Newark, NJ. His medical licensure includes certifications from the American Board of Ophthalmology in Neuro-ophthalmology and Ophthalmic Plastic/Reconstructive & Orbital Surgery. His research and clinical expertise encompass a range of topics including meningioma, pseudotumor cerebri, temporal arteritis, thyroid disease, and emerging techniques in orbital surgery.

Research topics

• Surgery
• Medicine
• Ophthalmology

Selected publications

• Orbital cellulitis, sinusitis and intracranial abnormalities in two adolescents with COVID-19

  Orbit · 2020 · 106 citations

  1st authorCorresponding

  We review two cases of adolescents with orbital cellulitis, sinusitis and SARS- CoV-2 infection presenting to emergency departments within a 24 hour period. SARS-CoV-2 samples obtained within 24 hours were positive, supporting prior infection despite relatively limited early symptoms of COVID-19. Unusual clinical and radiographic characteristics included hemorrhagic abscess with blood of varying age in the first, intracranial epidural abscess in the second, radiographic signal consistent with he…

  PublisherDOI

• Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study

  American Journal of Ophthalmology Case Reports · 2021 · 53 citations

  PURPOSE: To study post-interventional findings in patients with dysthyroid optic neuropathy (DON) treated with teprotumumab. OBSERVATIONS: patients with DON were treated with teprotumumab, an insulin-like growth factor I receptor inhibitor (10 mg/kg for the first infusion then 20 mg/kg for subsequent infusions, every three weeks for a total 8 infusions). This study included patients with acute and chronic thyroid eye disease (TED) with DON who had failed conventional therapies and were not candi…

  PublisherDOI

• Primary and Secondary Optic Nerve Sheath Meningioma

  Journal of Neurological Surgery Part B Skull Base · 2021-02-01 · 25 citations

  articleOpen accessSenior author

  Abstract Objective This study was aimed to review issues relating to the recognition, radiographic diagnosis, monitoring, and management of primary and secondary optic nerve sheath meningioma (ONSM). Design This study is a review of peer-reviewed literature combined with illustrative case studies. Participants and Methods A literature search was conducted via the PubMed database using pertinent search terms. Selected articles were limited to those written or translated into English. Additional w…

  PublisherOA PDFDOI

• Hybrid Schwannoma-Perineurioma of the Orbit

  Ophthalmic Plastic and Reconstructive Surgery · 2023-08-08 · 5 citations

  articleCorresponding

  A 52-year-old woman presented with a 6-month history of progressive right proptosis associated with intermittent right retrobulbar and facial pain. MRI revealed a heterogeneously enhancing, well-circumscribed, ovoid, soft tissue mass in the intraconal space near the right orbital apex displacing the optic nerve medially. Excisional biopsy established the diagnosis of a schwannoma-perineurioma hybrid peripheral nerve sheath tumor (HPNST). This case represents only the second reported occurrence,…

  PublisherDOI

• Phase 1/2 Clinical Study of VRDN-001, A Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients with Thyroid Eye Disease (TED) (P3-9.001)

  Neurology · 2023-04-25 · 5 citations

  article

  <h3>Objective:</h3> Report results from the first cohort of TED patients treated with 2 intravenous infusions of 10 mg/kg VRDN-001 from our phase 1/2 double-masked randomized clinical trial (NCT05176639). <h3>Background:</h3> IGF-1R antagonism can reduce TED-related inflammation and proptosis. We are evaluating VRDN-001, a full antagonist antibody to IGF-1R, in TED patients at doses of 3, 10, and 20 mg/kg. <h3>Design/Methods:</h3> Adults with active moderate-to-severe TED and clinical activity s…

  PublisherDOI

Frequent coauthors

• Larry Frohman

  Rutgers New Jersey Medical School

  115 shared

• Paul D. Langer

  Rutgers, The State University of New Jersey

  100 shared

• Luis M. Tumialán

  Barrow Neurological Institute

  82 shared

• Zachary Litvack

  Neuroscience Institute

  81 shared

• Nelson M. Oyesiku

  81 shared

• Chirag G. Patil

  Cedars-Sinai Medical Center

  81 shared

• Manish K. Aghi

  81 shared

• Gabriel Zada

  81 shared

Education

• B.A.

  Washington University

  1989

• B.S.

  Washington University

  1989

• M.D.

  University of Washington School of Medicine

  1993

Similar researchers at Rutgers University

• Joseph DeLucah-119
• Marco A. Zarbinh-62
• Peter S. Hershh-59